Biocon Biologics Acquires Pfizer's Research Facility to Expand its Research and Development Footprint
Shots:
- Biocon Biologics has acquired Pfizer’s 60-000 sq. ft state-of-the-art- bench to pilot scale R&D facility at TICEL Bio Park in Chennai- India
- The focus of the acquisition is to expand Biocon’s R&D capabilities and to accelerate the development of its biosimilars from lab to pilot scale- addressing the needs of patients globally
- The facility will house an early stage R&D center including pilot-scale R&D unit- equipped with cell line development- drug substance process development from bench scale to 400L scale bioreactors- drug product formulation laboratories- analytical R&D laboratories with 250+ scientists
Click here to read full press release/ article | Ref: Biocon | Image: Twitter
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com